Nuvation Bio Inc.

IPO

Nuvation Bio, Inc. | Oncology Drug Development

Public · New York, United States · Founded 2018 · $275.0M raised

Headquarters
New York, New York
Employees
51–200
Founded
2018
Business Model
B2B
Total Funding
$275.0M
Last Round
$275.0M Series AOct 2019
Rounds
1
Type
Public

About

Nuvation Bio Inc. (NYSE: NUVB) is a global oncology company founded in 2018 by biopharma veteran David Hung, M.D. The company develops differentiated and novel oncology treatments through proprietary drug discovery programs and business development. Its lead product IBTROZI (taletrectinib) is FDA-approved for ROS1-positive non-small cell lung cancer. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai.

Summary

Nuvation Bio Inc. is a Biotech company based in New York, United States, founded in 2018. It has raised $275.0M in total across 1 round, most recently a $275.0M Series A round in Oct 2019. Investors include Omega Funds, Aisling Capital and Altitude Life Science Ventures.

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

SPAC MergerSPAC MergerJan 2021

Sign up to see all 2 rounds

Series A through SPAC Merger — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Nuvation Bio Inc. on Indexed.vc
<a href="https://indexed.vc/companies/nuvation-bio-inc"><img src="https://indexed.vc/api/badge/company/nuvation-bio-inc" alt="Nuvation Bio Inc. on Indexed.vc" width="260" height="76" /></a>